ACY1 | Aminoacylase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins
| | | | | Group enriched |
ACY3 | Aspartoacylase (aminocyclase) 3 | Enzymes Predicted intracellular proteins
| | | | | Group enriched |
ADH1C | Alcohol dehydrogenase 1C (class I), gamma polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
ANXA10 | Annexin A10 | Predicted intracellular proteins
| | | | | Tissue enriched |
C16orf89 | Chromosome 16 open reading frame 89 | Predicted secreted proteins
| | | | | Group enriched |
CDX2 | Caudal type homeobox 2 | Cancer-related genes Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) | Cancer-related genes CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
LYZ | Lysozyme | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Group enriched |
MLN | Motilin | Predicted secreted proteins
| | | | | Tissue enriched |
MUC13 | Mucin 13, cell surface associated | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
OAT | Ornithine aminotransferase | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted intracellular proteins
| | | | | Group enriched |
PCK2 | Phosphoenolpyruvate carboxykinase 2 (mitochondrial) | Citric acid cycle related proteins Disease related genes Enzymes Mitochondrial proteins Plasma proteins Potential drug targets Predicted intracellular proteins
| | | | | Group enriched |
PDX1 | Pancreatic and duodenal homeobox 1 | Disease related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enriched |
SLC26A2 | Solute carrier family 26 (anion exchanger), member 2 | Disease related genes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
SULT1B1 | Sulfotransferase family, cytosolic, 1B, member 1 | Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
TMEM253 | Transmembrane protein 253 | Predicted membrane proteins
| | | | | Group enriched |
UGT2B17 | UDP glucuronosyltransferase 2 family, polypeptide B17 | Enzymes Predicted membrane proteins
| | | | | Group enriched |
HNF1A | HNF1 homeobox A | Cancer-related genes Predicted intracellular proteins
| | | | | Group enriched |
LGALS4 | Lectin, galactoside-binding, soluble, 4 | Cancer-related genes Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
MGAM | Maltase-glucoamylase (alpha-glucosidase) | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
NPC1L1 | NPC1-like 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
PADI2 | Peptidyl arginine deiminase, type II | Enzymes Predicted intracellular proteins
| | | | | Group enriched |
PLCB3 | Phospholipase C, beta 3 (phosphatidylinositol-specific) | Enzymes Predicted intracellular proteins
| | | | | Group enriched |
SATB2 | SATB homeobox 2 | Disease related genes Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
SST | Somatostatin | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
TFF2 | Trefoil factor 2 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enriched |
TRPM5 | Transient receptor potential cation channel, subfamily M, member 5 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
VIP | Vasoactive intestinal peptide | Cancer-related genes Predicted intracellular proteins Predicted secreted proteins
| | | | | Group enriched |
A1CF | APOBEC1 complementation factor | Predicted intracellular proteins
| | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) | Cancer-related genes CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
AGR2 | Anterior gradient 2 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AGR3 | Anterior gradient 3 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | Predicted intracellular proteins
| | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | Predicted intracellular proteins
| | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
ANXA13 | Annexin A13 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
APOA1 | Apolipoprotein A-I | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
BCAS1 | Breast carcinoma amplified sequence 1 | Predicted intracellular proteins
| | | | | Tissue enhanced |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
C15orf48 | Chromosome 15 open reading frame 48 | Predicted intracellular proteins
| | | | | Tissue enhanced |
C1orf106 | Chromosome 1 open reading frame 106 | Predicted intracellular proteins
| | | | | Tissue enhanced |
CA13 | Carbonic anhydrase XIII | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CALML4 | Calmodulin-like 4 | Predicted intracellular proteins
| | | | | Tissue enhanced |